



\$ 0400
07/16/02

Patent
Docket No: 54913US111

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

COLEMAN, et al

Serial No.: 10/027,218

Filed: December 21, 2001

For: AMIDE SUBSTITUTED IMIDAZOQUINOLINES

Group Art Unit:

Examiner:

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on:	
Date	Signature
July 11, 2002	Amber M. Stawiec

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97-1.98, copies of the documents listed on the attached form PTO-1449 are enclosed for consideration by the Examiner during examination of the above-identified patent application.

Should a First Office Action on the merits be mailed prior to the filing of this Disclosure Statement, please charge the requisite \$180.00 fee (pursuant to 37 C.F.R. §§ 1.97(c) and 1.17(p)) to Deposit Account No. 13-3723.

Registration Number 38,729	Telephone Number (651) 575-4914
Date 1 July 02	

Respectfully submitted,

By

Mary Susan Howard

Office of Intellectual Property Counsel
3M Innovative Properties Company
P.O. Box 33427
St. Paul, Minnesota 55133-3427
Facsimile: (651) 736-3833